Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis.
Liposomal-amphotericin B (L-AmB) is used for cutaneous leishmaniasis (CL); however, its treatment failure has not yet been described in detail. A 58-year-old man returned from the Republic of Venezuela with a cutaneous ulcer on his left lower leg. The causative pathogen was Leishmania braziliensis. We started L-AmB 3 mg/kg/day for 6 days; however, the ulcer did not resolve. The patient was successfully retreated with a higher dose L-AmB 4 mg/kg/day 9 times (total, 36 mg/kg). If L-AmB fails to treat CL and other therapeutics cannot be used, increasing the L-AmB dose is a viable option.
['Kosaka|Atsushi|A|', 'Sakamoto|Naoya|N|', 'Hikone|Mayu|M|', 'Imai|Kazuo|K|', 'Ota|Masayuki|M|', 'Washino|Takuya|T|', 'Maeda|Takuya|T|', 'Iwabuchi|Sentarou|S|']
D000666:Amphotericin B D000981:Antiprotozoal Agents D003937:Diagnosis, Differential D004305:Dose-Response Relationship, Drug D006801:Humans D007892:Leishmania braziliensis D016773:Leishmaniasis, Cutaneous D008297:Male D008875:Middle Aged D019233:Retreatment D017211:Treatment Failure
liposomal-amphotericin B cutaneous leishmaniasis Leishmania braziliensis